ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
Title of Each Class |
Trading Symbol (s) |
Name of Each Exchange on Which Registered | ||
Units, each consisting of one share of Class A common stock and one-half of one Redeemable Warrant |
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ||||
Emerging growth company |
Page |
||||||
Item 1. |
6 |
|||||
Item 1A. |
16 |
|||||
Item 1B. |
54 |
|||||
Item 2. |
54 |
|||||
Item 3. |
54 |
|||||
Item 4. |
54 |
|||||
Item 5. |
55 |
|||||
Item 6. |
55 |
|||||
Item 7. |
56 |
|||||
Item 7A. |
61 |
|||||
Item 8. |
61 |
|||||
Item 9. |
61 |
|||||
Item 9A. |
61 |
|||||
Item 9B. |
62 |
|||||
Item 9C. |
62 |
|||||
Item 10. |
63 |
|||||
Item 11. |
68 |
|||||
Item 12. |
69 |
|||||
Item 13. |
72 |
|||||
Item 14. |
73 |
|||||
PART IV |
||||||
Item 15. |
74 |
|||||
Item 16. |
75 |
|||||
1 |
• | “advisory board” are to the members of the advisory board set forth in this Annual Report; |
• | “amended and restated certificate of incorporation” are to the amended and restated certificate of incorporation of the company in effect on the date hereof; |
• | “anchor investors” are to the certain qualified institutional buyers or institutional accredited investors, as defined in Rule 144A and Regulation D, respectively, under the Securities Act, which are not affiliated with us, our sponsor, our directors or any member of our management and that purchased an aggregate of approximately 22,980,000 units in our initial public offering at the public offering price; |
• | “BH3 Management” are to BH3 Management LLC, a Delaware limited liability company; |
• | “common stock” are to our Class A common stock and our Class B common stock, collectively; |
• | “DGCL” are to the Delaware General Corporation Law as the same may be amended from time to time; |
• | “equity-linked securities” are to any debt or equity securities that are convertible into, or exercisable or exchangeable for, shares of our Class A common stock issued in connection with our initial business combination including but not limited to a private placement of equity or debt; |
• | “founders” are to Daniel Lebensohn and Gregory Freedman; |
• | “founder shares” are to the shares of our Class B common stock initially purchased by our sponsor and directors in a private placement prior to our initial public offering (and a portion of which were sold to our anchor investors on the date of our initial public offering), and the shares of our Class A common stock that will be issued upon the automatic conversion of the shares of our Class B common stock at the time of our initial business combination (for the avoidance of doubt, such shares of our Class A common stock will not be “public shares”); |
• | “initial stockholders” are to the holders of our founder shares prior to our initial public offering (other than the anchor investors), and where the context so requires, includes our anchor investors to the extent that they purchased founder shares from our sponsor on or about the date of our initial public offering; |
• | “investment committee” are to any officers, directors, advisory board members, or third party consultants appointed to the investment committee as set forth in this Annual Report or that may be appointed to the investment committee from time to time after the date hereof; |
• | “management” or our “management team” are to our executive officers; |
• | “private placement warrants” are to the warrants purchased by our sponsor in a private placement simultaneously with the closing of our initial public offering and upon conversion of working capital loans, if any; |
• | “public shares” are to shares of our Class A common stock sold as part of the units in our initial public offering (whether they were purchased in the initial public offering or thereafter in the open market); |
• | “public stockholders” are to the holders of our public shares, including our initial stockholders and management team to the extent our initial stockholders and/or members of our management team purchase public shares, provided that each of our initial stockholder’s and member of our management team’s status as a “public stockholder” will only exist with respect to such public shares; |
• | “public warrants” are to our redeemable warrants included in the units offered in our initial public offering (whether they are purchased in our initial public offering or thereafter in the open market) and to the private placement warrants if held by third parties other than our sponsor or its permitted transferees; |
• | “sponsor” is to Crixus BH3 Sponsor LLC, a Delaware limited liability company; |
• | “team” or our “sponsor team” are to our management team, our independent directors, and our advisory board; |
• | “warrants” are to the public warrants and the private placement warrants; and |
• | “we,” “us,” “our,” “company” or “our company” are to Crixus BH3 Acquisition Company, a Delaware corporation. |
• | our ability to select an appropriate target business or businesses; |
• | our ability to complete our initial business combination; |
• | our expectations around the performance of a prospective target business or businesses; |
• | our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; |
• | our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination; |
• | our potential ability to obtain additional financing to complete our initial business combination; |
• | our pool of prospective target businesses; |
• | our ability to consummate an initial business combination due to the uncertainty resulting from the recent COVID-19 pandemic and other events (such as terrorist attacks, natural disasters or a significant outbreak of other infectious diseases); |
• | the ability of our sponsor team to generate a number of potential investment opportunities; |
• | our public securities’ potential liquidity and trading; |
• | the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; |
• | the trust account not being subject to claims of third parties; or |
• | our financial performance following this offering. |
• | Strong Fundamentals |
• | Hidden Value |
• | Attractive Risk Adjusted Returns |
• | Proven Unit Economics and Growing Companies . |
• | Competitive Position |
• | Capable Management Team . |
• | Benefit from Being a Public Company . |
• | Potential for Stable Free Cash Flow |
• | financial condition and results of operations; |
• | growth potential; |
• | experience and skill of management and availability of additional personnel; |
• | capital requirements; |
• | stage of development of the business and its products or services; |
• | degree of current or potential market acceptance of the products or services; |
• | proprietary aspects of products and the extent of intellectual property or other protection for products or formulas; |
• | impact of regulatory environment and potential future regulation on the business; |
• | seasonal sales fluctuations and the ability to offset these fluctuations through other acquisitions, introduction of new products, or product line extensions; and |
• | the amount of working capital available. |
• | We are a recently incorporated company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective. |
• | Past performance by our sponsor team or their respective affiliates (including our founders) may not be indicative of future performance of an investment in us or in the future performance of any business that we may acquire. |
• | Our public stockholders may not be afforded an opportunity to vote on our proposed initial business combination, and even if we have a vote, holders of our founder shares will participate in such vote, which means we may complete our initial business combination even though a majority of our public stockholders do not support such a combination. |
• | Your only opportunity to affect the investment decision regarding a potential business combination will be limited to the exercise of your right to redeem your shares from us for cash, unless we seek stockholder approval of such business combination. |
• | Participation in the initial public offering by the anchor investors could reduce the public float for our securities, and could result in our inability to satisfy the Nasdaq continued listing requirements. |
• | Our outstanding warrants may have an adverse effect on the market price of our common stock and make it more difficult to effectuate our initial business combination. |
• | We may issue additional shares of capital stock or debt securities to complete a business combination, which would reduce the equity interest of our stockholders and likely cause a change in control of our ownership. |
• | We may be unable to obtain additional financing, if required, to complete a business combination or to fund the operations and growth of the target business. |
• | Resources could be wasted in researching acquisitions that are not consummated, which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. |
• | Our search for a business combination, and any target business with which we ultimately consummate a business combination, may be materially adversely affected by the recent coronavirus (COVID-19) pandemic and other events, and the status of debt and equity markets. |
• | We may have a limited ability to assess the management of a prospective target business and, as a result, may consummate our initial business combination with a target business whose management may not have the skills, qualifications or abilities to manage a public company. |
• | There may be tax consequences to our initial business combination that may adversely affect us. |
• | Our officers and directors presently have fiduciary or contractual obligations to other entities and, accordingly, may have conflicts of interest in determining to which entity a particular business opportunity should be presented. |
• | Our officers and directors may have interests in a potential business combination that are different than yours, which may create conflicts of interest. |
• | Nasdaq may delist our securities from trading on its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions. |
• | We may amend the terms of the warrants in a manner that may be adverse to holders of public warrants with the approval by the holders of at least a majority of the then outstanding public warrants. |
• | Our warrants are accounted for as a warrant liability and will be recorded at fair value upon issuance with changes in fair value for each period reported in earnings, which may have an adverse effect on the market price of our common stocks or may make it more difficult for us to consummate an initial business combination. |
• | Our warrant agreement designated the courts of the State of New York or the United States District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions. |
• | We may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants effectively worthless. |
• | If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per share redemption amount received by stockholders may be less than $10.10 per share. |
• | Provisions in our amended and restated certificate of incorporation and bylaws and Delaware law may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our common stock and could entrench management. |
• | Our amended and restated certificate of incorporation provides, subject to limited exceptions, that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain stockholder litigation matters, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or stockholders. |
• | Our stockholders may be held liable for claims by third parties against us to the extent of distributions received by them upon redemption of their shares. |
• | We may not hold an annual meeting of stockholders until after the consummation of our initial business combination. |
• | If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted, which may make it difficult for us to complete our initial business combination. |
• | We are an emerging growth company and a smaller reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies. |
• | Cyber incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss. |
• | restrictions on the nature of our investments; and |
• | restrictions on the issuance of securities, each of which may make it difficult for us to complete our initial business combination. |
• | registration as an investment company; |
• | adoption of a specific form of corporate structure; and |
• | reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations. |
• | default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; |
• | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
• | our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand; |
• | our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding; |
• | our inability to pay dividends on our Class A common stock; |
• | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our Class A common stock if declared, our ability to pay expenses, make capital expenditures and acquisitions and fund other general corporate purposes; |
• | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
• | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and |
• | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements and execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt. |
• | solely dependent upon the performance of a single business, property or asset; or |
• | dependent upon the development or market acceptance of a single or limited number of products, processes or services. |
• | costs and difficulties inherent in managing cross-border business operations and complying with different commercial and legal requirements of overseas markets; |
• | rules and regulations regarding currency redemption; |
• | complex corporate withholding taxes on individuals; |
• | laws governing the manner in which future business combinations may be effected; |
• | exchange listing and/or delisting requirements; |
• | tariffs and trade barriers; |
• | regulations related to customs and import/export matters; |
• | local or regional economic policies and market conditions; |
• | unexpected changes in regulatory requirements; |
• | longer payment cycles; |
• | tax issues, such as tax law changes and variations in tax laws as compared to the United States; |
• | currency fluctuations and exchange controls; |
• | rates of inflation; |
• | challenges in collecting accounts receivable; |
• | cultural and language differences; |
• | employment regulations; |
• | underdeveloped or unpredictable legal or regulatory systems; |
• | corruption; |
• | protection of intellectual property; |
• | social unrest, crime, strikes, riots and civil disturbances; |
• | regime changes and political upheaval; |
• | terrorist attacks, natural disasters and wars; |
• | deterioration of political relations with the United States; and |
• | government appropriation of assets. |
• | a limited availability of market quotations for our securities; |
• | reduced liquidity for our securities; |
• | a determination that our Class A common stock is a “penny stock” which will require brokers trading in our Class A common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; |
• | a limited amount of news and analyst coverage; and |
• | a decreased ability to issue additional securities or obtain additional financing in the future. |
• | may significantly dilute the equity interest of investors in the initial public offering; |
• | may subordinate the rights of holders of our Class A common stock if shares of preferred stock are issued with rights senior to those afforded our Class A common stock; |
• | could cause a change in control if a substantial number of shares of our Class A common stock is issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; |
• | may adversely affect prevailing market prices for our units, Class A common stock and/or warrants; and |
• | will not result in adjustment to the exercise price of our warrants. |
• | we have a board that includes a majority of ‘independent directors,’ as defined under the rules of Nasdaq; |
• | we have a compensation committee of our board that is comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and |
• | we have independent director oversight of our director nominations. |
• | because there are no authorities that directly address instruments similar to the units we are issuing in the initial public offering, the allocation an investor makes with respect to the purchase price of the unit between the share of common stock and one-half of one warrant included in the unit could be challenged by the Internal Revenue Service of the United States (“IRS”) or the courts. |
• | if we make distributions on our common stock, such distributions generally will be treated as dividends for U.S. federal income tax purposes to the extent of our current or accumulated earnings and profits. The ability of a holder to seek redemption of their shares may be viewed as a position with respect to substantially similar or related property which diminishes your risk of loss and thereby affects your ability to satisfy the holding period requirements for the dividends received deduction or the preferential tax rate on qualified dividend income with respect to the time period prior to the approval of an initial business combination. |
• | our warrants may be exercised on a cashless basis in certain situations as described in this Annual Report. Although there is no direct legal authority as to the U.S. federal income tax treatment of an exercise of a warrant on a cashless basis, we intend to take the position that such exercise will not be taxable, either because the exercise is not a gain realization event or because it qualifies as a tax-free recapitalization. |
• | any capital gain or loss you realize on a sale or other disposition of our common stock will generally be long-term capital gain or loss if your holding period for the common stock is more than one year. However, the redemption feature of the common stock could affect your ability to satisfy the holding period requirements for the long-term capital gain tax rate with respect to the time period prior to the approval of an initial business combination. |
ITEM 1B. |
UNRESOLVED STAFF COMMENTS |
ITEM 2. |
PROPERTIES |
ITEM 3. |
LEGAL PROCEEDINGS |
ITEM 4. |
MINE SAFETY DISCLOSURES |
For the Period from February 23, 2021 (Date of Inception) Through December 31, 2021 |
||||
Net Income |
$ | 12,427,342 | ||
|
|
|||
Accretion of Class A common stock to redemption amount |
$ | (37,127,388 | ) | |
|
|
|||
Net loss including accretion of temporary equity to redemption value |
$ | (24,700,046 | ) | |
|
|
For the Period from February 23, 2021 (Date of Inception) Through December 31, 2021 |
||||||||
Class A |
Class B |
|||||||
Basic and diluted net income (loss) per share: |
||||||||
Numerator: |
||||||||
Net loss including accretion of temporary equity to redemption value |
$ | (13,458,849 | ) | $ | (11,241,197 | ) | ||
Accretion of Class A common stock to redemption amount |
37,127,388 | — | ||||||
|
|
|
|
|||||
Net income (loss) |
$ | 23,668,539 | $ | (11,241,197 | ) | |||
|
|
|
|
|||||
Denominator: |
||||||||
Weighted Average Shares |
6,884,354 | 5,750,000 | ||||||
|
|
|
|
|||||
Basic and diluted income (loss) per ordinary share |
$ | 3.44 | $ | (1.95 | ) | |||
|
|
|
|
ITEM 9B. |
OTHER INFORMATION |
ITEM 9C. |
DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS |
Name |
Age |
Position | ||
Daniel Lebensohn | 50 | Co-Chief Executive Officer and Director | ||
Gregory Freedman | 41 | Co-Chief Executive Officer, Chief Financial Officer and Director | ||
Eric Edidin | 50 | Director | ||
Michelle Guber | 35 | Chief Operating Officer | ||
Daniel Adan | 38 | Director | ||
Dwight “Arne” Arnesen | 66 | Director | ||
Jonathan Roth | 59 | Director | ||
Mark Rose | 58 | Director |
• | appointing, replacing, compensating and overseeing our independent registered public accounting firm; |
• | reviewing and approving the annual audit plan for the Company; |
• | overseeing the integrity of our financial statements and our compliance with legal and regulatory requirements; |
• | discussing the annual audited financial statements and unaudited quarterly financial statements with management and the independent registered public accounting firm; |
• | pre-approving all audit services and permitted non-audit services to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed; |
• | establishing procedures for the receipt, retention and treatment of complaints (including anonymous complaints) we receive concerning accounting, internal accounting controls, or auditing matters; |
• | approving audit and non-audit services provided by our independent registered public accounting firm; |
• | discussing earnings press releases and financial information provided to analysts and rating agencies; |
• | discussing with management our policies and practices with respect to risk assessment and risk management; and |
• | producing an annual report for inclusion in our proxy statement, in accordance with applicable rules and regulations. |
• | evaluating our executive officers’ performance, including CEO performance, and setting our executive officers’ compensation level based on this evaluation; |
• | discharging its responsibilities for approving and evaluating the officer compensation plans, policies and programs of the Company; |
• | reviewing and recommending to our board of directors the compensation to be provided to the Company’s employees and directors; |
• | recommending awards and/or bonuses to be granted to executive officers of the Company under the Company’s equity plans and other compensation or benefit plans or policies as approved by our board of directors or the compensation committee; |
• | reviewing with management the Company’s Compensation and Discussion and Analysis (“CD&A”) and the related executive compensation information, recommending that the CD&A and related executive compensation information be included in the Company’s annual report on Form 10-K and proxy statement and produce the compensation committee report on executive officer compensation required to be included in the Company’s proxy statement or annual report on Form 10-K; |
• | reviewing the form, terms and provisions of employment and similar agreements with the Company’s executive officers and any amendments thereto; |
• | approving all special perquisites, special cash payments and other special compensation and benefit arrangements for the Company’s executive officers and employees; and |
• | retaining outside consultants and obtain assistance from members of management, in each case as the compensation committee deems appropriate in the exercise of its authority. |
• | each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock; |
• | each of our executive officers and directors that beneficially owns shares of common stock; and |
• | all our executive officers and directors as a group. |
Name and Address of Beneficial Owner(1) |
Number of Shares Beneficially Owned(2) |
Approximate Percentage of Outstanding Common Stock |
||||||
Crixus BH3 Sponsor LLC |
4,139,242 | (3) |
14.4 | % | ||||
Daniel Lebensohn |
4,139,242 | (3) |
14.4 | % | ||||
Gregory Freedman |
4,139,242 | (3) |
14.4 | % | ||||
Eric Edidin |
— | (4) |
— | |||||
Michelle Guber |
— | (5) |
— | |||||
Daniel Adan |
40,000 | (6) |
* | |||||
Dwight “Arne” Arnesen |
40,000 | (6) |
* | |||||
Jonathan Roth |
40,000 | (6) |
* | |||||
Mark Rose |
40,000 | (6) |
* | |||||
All executive officers and directors as a group (eight individuals) |
4,299,242 | 15.0 | % | |||||
Name and Address of Beneficial Owner |
Number of Shares Beneficially Owned |
Approximate Percentage of Outstanding Common Stock |
||||||
Weiss Asset Management LP (7) |
1,980,000 | 8.6 | % | |||||
Atlas Diversified Master Fund, Ltd. (8) |
1,980,000 | 8.6 | % | |||||
Highbridge Capital Management, LLC (9) |
1,176,308 | 5.1 | % | |||||
683 Capital Management, LLC (10) |
1,980,000 | 8.6 | % | |||||
Polar Asset Management Partners Inc. (11) |
1,980,000 | 8.6 | % | |||||
Shaolin Capital Management LLC (12) |
1,201,900 | 5.2 | % | |||||
Castle Creek Arbitrage, LLC (13) |
1,980,000 | 8.6 | % | |||||
Periscope Capital Inc. (14) |
1,154,100 | 5.0 | % |
* | Less than one percent. |
(1) | Unless otherwise noted, the business address of each of our stockholders is c/o Crixus BH3 Acquisition Company, 819 NE 2 nd Avenue, Suite 500, Fort Lauderdale, FL 33304. |
(2) | Interests shown consist solely of founder shares, which are Class B shares of common stock. Such shares are not convertible into shares of Class A common stock within 60 days of the date of this Annual Report but will automatically convert into shares of Class A common stock on the first business day following the completion of our initial business combination. |
(3) | Our sponsor is controlled by BH3 Management LLC, an entity owned and controlled indirectly by Messrs. Lebensohn and Freedman. Messrs. Lebensohn and Freedman indirectly share voting and dispositive power over the founder shares held by our sponsor and may be deemed to beneficially own the founder shares. Includes 280,261 and 280,261 founder shares, respectively, owned by our sponsor as a result of their respective indirect membership interests in our sponsor. Each of Messrs. Lebensohn and Freedman disclaims beneficial ownership of the founder shares held by our sponsor other than to the extent of his respective pecuniary interest in such founder shares. Each of our officers and directors are direct or indirect members of our sponsor, or have direct or indirect economic interests in our sponsor. |
(4) | Excludes 236,528 founder shares owned by our sponsor as a result of Mr. Edidin’s membership interest in our sponsor since Mr. Edidin does not currently have voting or dispositive power over such founder shares. |
(5) | Excludes an indirect economic interest in the founder shares as a result of a limited profits interest held by Ms. Guber in BH3 Management LLC. |
(6) | Excludes 40,000 founder shares owned by our sponsor as a result of such director membership interest in our sponsor since such director does not currently have voting or dispositive power over such founder shares. |
(7) | According to a Schedule 13G/A filed with SEC on January 28, 2022 by (i) Weiss Asset Management LP, a Delaware limited partnership (“Weiss Asset Management”), (ii) BIP GP, LLC, a Delaware limited liability company (“BIP GP”), (iii) WAM GP LLC, a Delaware limited liability company (“WAM GP”), (iv) Andrew M. Weiss, a citizen of United States of America, each of Weiss Asset Management, WAM GP and Andrew M. Weiss may be deemed to beneficially own 1,980,000 shares of class A common stock of the Company, and BIP GP may be deemed to beneficially own 1,267,200 shares of class A common stock of the Company. Shares reported for BIP GP include shares beneficially owned by a private investment partnership (the “Partnership”) of which BIP GP is the sole general partner. Weiss Asset Management is the sole investment manager to the Partnership. WAM GP is the sole general partner of Weiss Asset Management. Andrew Weiss is the managing member of WAM GP and BIP GP. Shares reported for WAM GP, Andrew Weiss and Weiss Asset Management include shares beneficially owned by the Partnership (and reported above for BIP GP). Each of BIP GP, WAM GP, Weiss Asset Management, and Andrew Weiss disclaims beneficial ownership of the shares reported herein as beneficially owned by each except to the extent of their respective pecuniary interest therein. The business address of each of the reporting persons is 222 Berkeley St., 16 th Floor, Boston, Massachusetts 02116. |
(8) | According to a Schedule 13G/A filed with SEC on February 14, 2022 by (i) Atlas Diversified Master Fund, Ltd, a Cayman corporation (“ADMF”), (ii) Atlas Diversified Fund, Ltd., a Cayman corporation (“ADF LTD”), (iii) Atlas Diversified Fund, L.P., a Delaware limited partnership (“ADF LP”), (iv) Atlas Master Fund, Ltd., a Cayman corporation (“AMF”), (v) Atlas Global, LLC, a Delaware limited liability company (“AG”), (vi) Atlas Global Investments, Ltd., a Cayman corporation (“AGI”), (vii) Atlas Enhanced Master Fund, Ltd., a Cayman corporation (“AEMF”), (viii) Atlas Enhanced Fund, L.P., a Delaware limited partnership (“AEF LP”), (ix) Atlas Enhanced Fund, Ltd., a Cayman corporation (“AEF LTD”), (x) Atlas Portable Alpha, LP, a Delaware limited partnership (“APA LP”), (xi) Atlas, Terra Fund, Ltd., a Cayman corporation (“ATF LTD”), (xii) Atlas Institutional Equity Fund, L.P., a Delaware limited partnership (“AIEF LP”), (xiii), Balyasny Asset Management L.P., a Delaware limited partnership (“BAM”), and (xiv) Dmitry Balyasny, a United States citizen, each of ADMF, ADF LTD, ADF LP, BAM and Dmitry Balyasny may be deemed to beneficially own 1,980,000 shares of class A common stock of the Company, each of AMF, AG and AGI may be deemed to beneficially own 141,736 shares of class A common stock of the Company, and each of AEMF, AEF LP, AEF LTD, APA LP, ATF LTD, and AIEF LP may be deemed to beneficially own 1,838,264 shares of class A common stock of the Company. The business address of ADMF, ADF LTD, AMF, AGI, AEMF, AEF LTD, and ATF LTD is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. The business address of ADF LP, AG, AEF LP, APA LP, AIEF LP, BAM and Dmitry Balyasny is 444 West Lake Street, 50th Floor, Chicago, IL 60606. |
(9) | According to a Schedule 13G/A filed with SEC on February 3, 2022 by Highbridge Capital Management, LLC, a Delaware limited liability company and the investment adviser to certain funds and accounts (the “Highbridge Funds”). The business address of Highbridge Capital Management, LLC is 277 Park Avenue, 23 rd Floor, New York, New York 10172. |
(10) | According to a Schedule 13G filed with SEC on October 26, 2021 by (i) 683 Capital Management, LLC, a Delaware limited liability company, (ii) 683 Capital Partners, LP, a Delaware limited partnership and (iii) Ari Zweiman, a citizen of the United States, each of the reporting persons may be deemed to beneficially own 1,980,000 shares of common stock of the Company. The business address of each of the reporting persons is 3 Columbus Circle, Suite 2205, New York, NY 10019. |
(11) | According to a Schedule 13G filed with SEC on February 8, 2022 by Polar Asset Management Partners Inc., a company incorporated under the laws of Ontario, Canada, which serves as the investment advisor to Polar Multi-Strategy Master Fund, a Cayman Islands exempted company (“PMSMF”) with respect to the Shares (as defined below) directly held by PMSMF. The business address of the reporting person is 16 York Street, Suite 2900, Toronto, ON, Canada M5J 0E6. |
(12) | According to a Schedule 13G filed with SEC on February 11, 2022 by Shaolin Capital Management LLC, a company incorporated under the laws of State of Delaware, which serves as the investment advisor to Shaolin Capital Partners Master Fund, Ltd. a Cayman Islands exempted company, MAP 214 Segregated Portfolio, a segregated portfolio of LMA SPC, and DS Liquid DIV RVA SCM LLC being managed accounts advised by the Shaolin Capital Management LLC. The business address of the reporting person is 7610 NE 4th Court, Suite 104 Miami FL 33138. |
(13) | According to a Schedule 13G filed with SEC on February 11, 2022 by (i) Castle Creek Arbitrage, LLC, a Delaware limited liability company, (“Castle Creek”), (ii) Mr. Allan Weine, as the principal beneficial owner of Castle Creek Arbitrage, LLC, a US citizen (iii) CC ARB West, LLC is a Delaware limited liability company, and (iv) CC Arbitrage, Ltd. is a Cayman Island Company, each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Castle Creek Arbitrage, LLC serves as a registered investment adviser whose clients are CC Arb West, LLC and CC Arbitrage, Ltd. Mr. Weine is the managing member of Castle Creek. By virtue of these relationships, each of Castle Creek and Mr. Weine may be deemed to beneficially own the Issuer’s Common Shares directly owned by CC ARB West, LLC and CC Arbitrage, Ltd. The business address of each of the Reporting Persons is 190 South LaSalle Street, Suite 3050, Chicago, Illinois 60603. |
(14) | According to a Schedule 13G filed with SEC on February 14, 2022 by Periscope Capital Inc. (“Periscope”), a Canada corporation, which is the beneficial owner of 1,000,000 shares of Common Stock, acts as investment manager of, and exercises investment discretion with respect to, certain private investment funds that collectively directly own 154,100 shares of Common Stock. The business address of Periscope is 333 Bay Street, Suite 1240, Toronto, Ontario, Canada M5H 2R2. |
32.1** | Certification of Co-Chief Executive Officers required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350. | |
32.2** | Certification of Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350. | |
101.INS* | Inline XBRL Instance Document. | |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | |
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |
104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
* | Filed herewith. |
** | Furnished herewith. |
(1) | Incorporated by reference to an exhibit to the Registrant’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 7, 2021. |
(2) | Incorporated by reference to an exhibit to the Registrant’s Form S-1 (File No. 333-259269), filed with the SEC on September 29, 2021. |
Page |
||||
PCAOB ID ( |
||||
F-1 |
||||
F-2 |
||||
F-3 |
||||
F-4 |
||||
F-5 |
||||
F-6- to F-19 |
Assets: |
||||
Current assets |
||||
Cash |
$ | |||
Prepaid expenses |
||||
Total current assets |
||||
Cash and marketable securities held in Trust Account |
||||
Total Assets |
$ |
|||
Liabilities and Stockholders’ Equity: |
||||
Current Liabilities: |
||||
Accrued expenses |
||||
Derivative Warrant Liability |
||||
Total current liabilities |
||||
Deferred underwriting fee payable |
||||
Total Liabilities |
$ |
|||
Commitments and Contingencies: |
||||
Temporary Equity: |
||||
Class A common stock, $ |
||||
Stockholders’ Equity (Deficit): |
||||
Preferred stock, $ |
||||
Class B common stock, $ |
||||
Accumulated Deficit |
( |
) | ||
Total Stockholders’ Equity |
( |
) | ||
Total Liabilities, Temporary Equity and Stockholders’ equity |
$ |
Loss from operations |
$ |
( |
) | |
Change in fair market value of derivative warrant liability |
||||
Offering costs allocated to public warrants |
( |
) | ||
Other Expenses: |
||||
Investment losses |
( |
) | ||
Total other expense |
( |
) | ||
Net Income |
$ |
|||
Basic and diluted weighted average shares outstanding, Class A common stock |
||||
Net Income per share, Class A common stock |
$ |
|||
Basic and diluted weighted average shares outstanding, Class B common stock |
||||
Net Loss per share, Class B common stock |
$ |
( |
) |
Class A |
Class B |
Additional |
||||||||||||||||||||||||||
Common Stock |
Common Stock |
Paid in |
Accumulated |
|||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
Capital |
Deficit |
Total |
||||||||||||||||||||||
Balance - February 23, 2021 (Date of Inception) |
$ | $ | $ | $ | $ | |||||||||||||||||||||||
Issuance of Class B common stock to Sponsor |
— | — | — | |||||||||||||||||||||||||
Temporary Equity Sale of |
— | — | — | |||||||||||||||||||||||||
Common Stock subject to redemptions |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Net Income |
— | — | — | — | — | |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance Ending December 31, 2021 |
$ | $ | $ | $ | ( |
) | $ | ( |
) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flow from operating activities: |
||||
Net Income |
$ | |||
Adjustments to reconcile net income to net cash used in operating activities: |
||||
Investment Losses |
||||
Change in fair market value of derivative warrant liability |
( |
) | ||
Offering costs allocated to public warrants |
||||
Changes in operating assets and liabilities: |
||||
Prepaid Expenses |
( |
) | ||
Accrued Expenses |
||||
Net cash used in operating activities |
( |
) | ||
Cash flow from investing activities: |
||||
Investment of cash in Trust Account |
( |
) | ||
Net cash used in investing activities |
( |
) | ||
Cash flows from financing activities: |
||||
Proceeds from sale of Units, net of underwriting discounts paid |
||||
Proceeds from issuance of Class B common stock to Sponsor |
||||
Proceeds from sale of warrants |
||||
Payment of offering costs |
( |
) | ||
Proceeds from promissory note - related party |
||||
Repayment of promissory note - related party |
( |
) | ||
Net cash provided by financing activities |
||||
Net change in cash |
||||
Cash at the beginning of the period |
||||
Cash at the end of the period |
$ | |||
Non-Cash investing and financing activities: |
||||
Deferred underwriting fee payable |
$ | ( |
) | |
Share consideration to anchor investors |
$ |